IDEAYA Biosciences, Inc.
IDEAYA Biosciences is a clinical-stage precision oncology company focused on discovering and developing targeted cancer therapies matched to specific molecular alterations. Its pipeline centers on small-molecule programs, synthetic lethality, and antibody-drug conjugates, with development guided by companion diagnostics and biomarker selection.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueClinical development of darovasertib for uveal melanoma, including combination and registrational studies.
Antibody-drug conjugate and DNA damage response combination programs in molecularly defined solid tumors.
Targeted therapies aimed at MTAP-deleted cancers and related synthetic lethality biology.
Earlier-stage discovery and development programs beyond the current lead assets.
Revenue from partnered R&D, licensing, milestones, and diagnostic-enabling activities.
Customers
IDEAYA does not yet sell approved products; its current counterparties are pharmaceutical partners, diagnostic companies, and clinical investigators rather than end patients. If approved, its medicines would be used by oncologists treating molecularly defined cancer populations, with commercialization initially planned in the United States and selectively abroad. The company also relies on diagnostic partners to identify eligible patients and on CMOs to manufacture clinical and future commercial supply.
Partners such as GSK, Servier, Pfizer, Gilead, Biocytogen, and Hengrui support development, licensing, supply, or commercialization of specific programs.
Companies like Foundation Medicine, Guardant Health, and Tempus help identify patients most likely to benefit from IDEAYA's therapies.
Academic and community oncology centers enroll patients into biomarker-selected studies and registrational trials.
Specialist oncologists would prescribe approved products for defined cancer subtypes if the pipeline reaches commercialization.
CMOs manufacture API, drug product, and related supply for preclinical, clinical, and future commercial use.
Strategy
IDEAYA's strategy is to build a precision oncology pipeline around molecularly defined cancers where biomarker selection can improve response rates and trial efficiency. It is prioritizing darovasertib, ADC/DDR combinations, and MTAP pathway programs while using partnerships to share development risk, access diagnostics, and extend commercialization reach. The company also plans to build a U.S. sales force only if and when products are approved, while relying on collaborators outside the U.S. where appropriate.
This is the most advanced asset and a potential first commercial product.
Diversifies the pipeline and creates multiple shots on goal in precision oncology.
Patient selection is central to the company's precision-medicine thesis and trial success.
Partnerships reduce capital needs and provide external validation for programs.
Geography
IDEAYA is headquartered in the United States and currently expects to commercialize any approved medicines first in the U.S., with potential expansion into Europe and other selected foreign markets. Outside the U.S., darovasertib commercialization is licensed to Servier, which makes international reach partner-dependent rather than fully owned. The company also depends on global diagnostic, manufacturing, and clinical trial networks to support its precision-medicine development model.
Risks
IDEAYA is a clinical-stage biotech with no approved products, so its value depends on successful trials, regulatory approvals, and eventual commercialization. The company also faces substantial financing, competition, and execution risk because it must fund long development cycles, outsource manufacturing, and build commercial capabilities if programs succeed. Precision oncology adds diagnostic and reimbursement risk, since therapies must be matched to the right patients and payors must accept the value proposition.
- Clinical development failureImpact: HighLikelihood: Medium
Pipeline value depends on demonstrating safety and efficacy in biomarker-defined cancers.
Exposure - Financing riskImpact: HighLikelihood: Medium
The company has significant losses and will likely need additional capital to fund development.
Exposure - Competition from larger oncology companiesImpact: MediumLikelihood: Medium
Rivals may develop similar targeted therapies faster or with greater resources.
Exposure - Commercialization and reimbursement riskImpact: MediumLikelihood: Medium
Even approved products may face payer resistance or limited reimbursement in niche indications.
Exposure: U.S. launch and future ex-U.S. markets
- Manufacturing and supply-chain dependenceImpact: MediumLikelihood: Medium
The company relies on third-party CMOs for API, drug product, and diagnostics supply.
Exposure: Clinical and future commercial supply
Accounting
Judgemental itemsRevenue from licenses, milestones, and R&D services is recognized under different timing rules.
Impact: Can cause large quarter-to-quarter swings in reported revenue
Upfront payments and reimbursable R&D create deferred revenue and receivable balances.
Impact: Affects balance sheet presentation and revenue timing
As a development-stage public biotech, equity compensation is likely a meaningful operating expense.
Impact: Impacts reported losses and non-cash expense trends
Cash runway includes money market funds, U.S. government securities, commercial paper, and corporate bonds.
Impact: Fair value changes can affect other comprehensive income and liquidity disclosure
Similar listed companies
Publicly listed companies with a comparable business focus.
Black Diamond Therapeutics, Inc.
BDTX · Biological Products, (No Diagnostic Substances)
Aura Biosciences, Inc.
AURA · Biological Products, (No Diagnostic Substances)
Aldeyra Therapeutics, Inc.
ALDX · Pharmaceutical Preparations
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on discovering and developing therapies for immune-mediated diseases.
Erasca, Inc.
ERAS · Pharmaceutical Preparations
Castle Biosciences, Inc
CSTL · Services-Medical Laboratories
Castle Biosciences is a U.S.-based molecular diagnostics company that develops tissue-based tests to help clinicians make treatment and diagnosis decisions in…
EyePoint, Inc.
EYPT · Laboratory Analytical Instruments
Last updated: 24/09/2026